ストックスクリーナーアプリを入手
12.79
0.39%
-0.05
アフターアワーズ：
12.80
0.01
+0.08%
前日終値:
$12.84
開ける：
$13.1
24時間の取引高:
1.21M
Relative Volume:
0.99
時価総額：
$732.39M
収益：
-
当期純損益:
$-52.79M
株価収益率:
-16.42
EPS:
-0.7789
ネットキャッシュフロー:
$-53.49M
1週間 パフォーマンス:
+4.66%
1か月 パフォーマンス:
-2.22%
6か月 パフォーマンス:
+149.80%
1年 パフォーマンス:
+782.07%
1日の値動き範囲:
$12.37
$14.41
1週間の範囲:
$12.25
$14.41
52週間の値動き範囲:
$1.36
$14.41
Climb Bio Inc Stock (CLYM) Company Profile
Compare CLYM vs VRTX, REGN, ARGX, RVMD, ALNY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
12.79 | 735.26M | 0 | -52.79M | -53.49M | -0.7789 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-15 | 開始されました | Mizuho | Outperform |
| 2026-03-24 | 開始されました | B. Riley Securities | Buy |
| 2026-03-18 | 開始されました | Truist | Buy |
| 2026-03-11 | 開始されました | Raymond James | Strong Buy |
| 2026-03-05 | 開始されました | Wedbush | Outperform |
| 2026-02-13 | 開始されました | Piper Sandler | Overweight |
| 2025-10-16 | 開始されました | William Blair | Outperform |
| 2025-10-13 | 開始されました | H.C. Wainwright | Buy |
| 2025-08-15 | 開始されました | Robert W. Baird | Outperform |
| 2025-06-06 | 開始されました | Oppenheimer | Outperform |
| 2025-05-22 | 開始されました | BTIG Research | Buy |
| 2024-12-02 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Climb Bio Inc (CLYM) 最新ニュース
Climb Bio Inc (CLYM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CLYM Maintained by Wedbush -- Price Target Raised to $20.00 - GuruFocus
Wedbush Raises Price Target on Climb Bio to $20 From $17, Keeps Outperform Rating - Moomoo
Climb Bio Inc (CLYM) Cash Flow - TradingKey
Climb Bio Inc (CLYM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Climb Bio Inc (CLYM) Institutional Confidence - TradingKey
Climb Bio Inc (CLYM) Valuation: PE, PB & Fair Value Analysis - TradingKey
CLYM|Climb Bio Inc|Price:12.840|Chg%:+0.080 - TradingKey
Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility (CLYM) - Seeking Alpha
Frontier tech research, news & data - MLQ.ai
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
FMR LLC's Strategic Acquisition of Climb Bio Inc Shares - GuruFocus
Q32 Bio Shares Climb Ahead of Drug Trial Results for Alopecia Treatment - Moomoo
Climb Bio Inc. (CLYM) Edges Lower Amid Mixed Biotech Sentiment, Key Support Levels in FocusWeak Sell Signals - DonanımHaber
Climb Bio Inc. (CLYM) Q1 2026 Earnings: Smaller-Than-Expected Loss Signals Cost DisciplineNegative Surprise Momentum - dars.gov.et
Climb Bio, Inc. advances CD19-based approach to preserve protective antibody function - Traders Union
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year? - Yahoo Finance
CLYM Q1 2026 Earnings: Narrower Loss than Expected, Stock Edges HigherPost-Announcement Reaction - DonanımHaber
Form 13D/A Climb Bio For: 7 July By Investing.com - Investing.com Nigeria
5 Biotech Stocks That Delivered 100% To 300% Gains: Did Your Winning Trades Offset Portfolio Losses? - RTTNews
Climb Bio Inc. (CLYM) Q1 2026 Earnings: EPS Beat Partially Offsets Market Skepticism as Pre-Revenue Biotech Navigates Clinical ProgressDividend Earnings Report - dars.gov.et
Climb Bio Appoints Breanna O’Reilly to Board - The Globe and Mail
Climb Bio, Inc. Files Form 8-K: Key Company Information, NASDAQ Listing, and Emerging Growth Status - Minichart
Form 4 Climb Bio Inc For: 1 July By Investing.com - Investing.com UK
70,284 Climb Bio (CLYM) share options granted for RA Capital-related funds - Stock Titan
Climb Bio (CLYM) director receives 70,284 stock options tied to RA Capital funds - Stock Titan
Climb Bio (CLYM) director Breanna Maurine Celebi files initial Form 3 - Stock Titan
Breanna O’Reilly joins Climb Bio (NASDAQ: CLYM) board with stock option grant - Stock Titan
Climb Bio, Inc. reveals on-target clinical results for budoprutug in new study - Traders Union
Climb Bio Insider Sold Shares Worth $406,979, According to a Recent SEC Filing - marketscreener.com
Form 4 Climb Bio Inc For: 30 June By Investing.com - Investing.com Canada
Form 144 CLIMB BIO For: 30 June By Investing.com - Investing.com Nigeria
Climb Bio CEO Aoife Brennan sells $406,979 in shares By Investing.com - Investing.com India
Climb Bio (CLYM) CEO sells 30,902 shares after RSU vesting - Stock Titan
[144] Climb Bio, Inc. SEC Filing - Stock Titan
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Index - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2500 Growth Benchmark - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Value Benchmark - marketscreener.com
Climb Bio, Inc. advances rare kidney disease collaboration with patient-centered approach - Traders Union
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Growth Benchmark - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 3000E Growth Benchmark - marketscreener.com
CLYM Q1 2026 Earnings: Narrowed Loss Beat Expectations as Biotech Continues Pipeline DevelopmentProfit Margin Analysis - dars.gov.et
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 3000 Index - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Dynamic Index - marketscreener.com
CLYM Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplineEarnings Expansion Phase - dars.gov.et
Climb Bio Q1 2026 Earnings: Bottom-Line Beat Provides Positive MomentumEPS Surprise History - dars.gov.et
Why is Climb Bio stock gaining Friday? - MSN
Price to sales forward of Climb Bio, Inc. – NASDAQ:CLYM - TradingView
Price to earnings forward of Climb Bio, Inc. – NASDAQ:CLYM - TradingView
Price to book forward of Climb Bio, Inc. – NASDAQ:CLYM - TradingView
Climb Bio Inc (CLYM) 財務データ
収益
当期純利益
現金流量
EPS
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):